Astria Therapeutics, Inc. (ATXS)
NASDAQ: ATXS · Real-Time Price · USD
9.58
-0.17 (-1.74%)
Nov 20, 2024, 4:00 PM EST - Market closed
Astria Therapeutics Employees
Astria Therapeutics had 59 employees as of December 31, 2023. The number of employees increased by 17 or 40.48% compared to the previous year.
Employees
59
Change (1Y)
17
Growth (1Y)
40.48%
Revenue / Employee
n/a
Profits / Employee
-$1,695,661
Market Cap
540.64M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Auna S.A. | 14,958 |
Fulgent Genetics | 1,184 |
Organogenesis Holdings | 862 |
Pharming Group | 382 |
SI-BONE | 344 |
Silence Therapeutics | 109 |
Mereo BioPharma Group | 33 |
Opthea | 33 |
ATXS News
- 7 days ago - Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update - Business Wire
- 7 days ago - Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference - Business Wire
- 16 days ago - Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 21 days ago - Astria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting - Business Wire
- 4 weeks ago - Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting - Business Wire
- 5 weeks ago - European Commission Grants Orphan Medicinal Product Designation for Navenibart, Astria Therapeutics' Investigational Therapy for the Treatment of Hereditary Angioedema - Business Wire
- 7 weeks ago - Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema - Business Wire
- 7 weeks ago - Astria Therapeutics to Present at Upcoming Global Angioedema Forum - Business Wire